



Vivimed

Date: 10.01.2025

To

BSE Limited
P.J.Towers, Dalal Street,
Mumbai – 400001
BSE - Code : 532660

National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex, Bandra (E)
Mumbai - 400 051
NSE- Symbol: VIVIMEDLAB

Dear Sir/Madam

Sub: Outcome of the Meeting of the Board of Directors of the Company – reg.

The Board of Directors of the Company at its meeting held on January 10, 2025 inter alia, have approved / resolved/ taken note of the following:

1. Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 considered and approved (1) The submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter ended June 30, 2024 & (2) The submission of the Un-audited Financial Results (Standalone & Consolidated) for the Quarter and half year ended September 30, 2024 attached herewith;
2. Auditors's Limited Review Report on (1) Un-audited Financial Results of the Company for the quarter ended June 30, 2024 & (2) Un-audited Financial Results of the Company for the quarter and half year ended September 30, 2024.
3. Appointment of Chief Financial Officer

In terms of Regulation 30 read with Schedule III Part A Para A (7) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Board of Directors of the Company at its meeting held today has appointed Mr. Phanindernath Petasonti, as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company with effect from 10.01.2025.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular CIR/CFD/CMD/4/2015 dated 9 September 2015 are attached as **Annexure**.


The Board meeting concluded at 23.50 Hrs.

You are requested to take note of the above.

Yours faithfully

For VIVIMED LABS LIMITED

**SANTOSH VARALWAR
MANAGING DIRECTOR**



Vivimed Labs Limited.

CIN : L02411KA1988PLC009465

Registered Office: #78/A, Kolhar Industrial Area,
Bidar, Karnataka-585 403, India

T+91 (0) 8482-232045, F+91 (0) 8482-232436

Email: info@vivimedlabs.com | www.vivimedlabs.com

Corporate Office:

6-3-866/1/G1, 3rd Floor, GMR Towers,
Greelands, Begumpet, Hyderabad
Telangana-5000 016, India.

GSTIN: 36AAACV6060A1ZQ

T 91(0) 40-6608-6608, F+91(0) 40-6608-6699

Annexure

Sl. No.	Particulars	Details of event
1	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointed Mr.Phanindernath Petasonti, as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the Company.
2	Date of appointment	10.01.2025
3	Brief profile	Qualification: Chartered Accountant Age: 57 Yrs Experience: 30 th Yrs. Post Qualification Experience in the field of Finance, Accounts, Software & Admin.
4	Disclosure of relationships between Directors	Mr.Phanindernath Petasonti is not related to any director/KMP of the Company.





VIVIMED LABS LIMITED

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

Rs. In Million

Sl. No.	Particulars	3 Months Ended			Previous Year Ended 31.03.2024
		30.06.2024	31.03.2024	30.06.2023	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from Operations	246.36	363.86	329.99	1,367.97
	Total revenue from operations	246.36	363.86	329.99	1,367.97
2	Other Income	0.03	73.69	0.08	95.72
3	Total Revenue (1+2)	246.39	437.55	330.06	1,463.69
4	Expenses				
a	Cost of material consumed	169.54	309.18	177.18	853.87
b	Purchases of Stock-in-Trade	-	-	-	-
c	Changes in inventories of finished goods work in progress and stock-in-Trade	(24.62)	(183.96)	(11.53)	(180.70)
d	Employee Benefit Expenses	49.52	56.91	65.72	294.48
e	Finance Costs	2.51	(336.91)	106.14	(9.04)
f	Depreciation and Amortisation Expenses	37.90	49.55	44.85	184.10
g	Other Expenses	162.66	413.68	91.55	678.43
	Total Expenses	397.50	306.45	483.88	1,849.22
5	Profit before tax (3-4)	(151.11)	131.10	(153.82)	(385.53)
6	Prior Period Expenses	-	58.29	-	58.29
7	Tax Expenses				
	Current Taxes	-	-	-	-
	Deferred Taxes	-	17.68	-	-
	Total tax expenses	-	17.68	-	-
8	Profit for the period (Year (5-6-7))	(151.11)	55.13	(153.82)	(443.82)
9	Other Comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax	-	4.76	-	4.76
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-
	Total other comprehensive income	-	4.76	-	4.76
10	Total comprehensive income (8+9)	(151.11)	59.89	(153.82)	(439.06)
11	Paid up Equity Share Capital	163.83	163.83	163.83	163.83
12	Other equity	-	-	-	-
13	Earnings per Share (before Extraordinary Items) of Rs2 - each				
	(a) Basic	(1.82)	0.66	(1.86)	(5.35)
	(b) Diluted	(1.77)	0.65	(1.80)	(5.20)

NOTES

- The above standalone financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 10, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and expressed a modified conclusion thereon.
- These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND-AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- In line with provisions of IND-AS 108 Operating segments, the Company has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.
- The Company has defaulted in repayment of dues to banks and Financial Institution amounting to Rs 3,746.46 million as on 30.06.2024 as per books of account. All the loan accounts outstanding as on 30.06.2024 are classified as NPA by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.
- Deferred tax will be calculated at the end of year.
- Corresponding numbers of previous period year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 10/01/2025



For VIVIMED LABS LIMITED
(SANTOSH VARALWAR)
MANAGING DIRECTOR

VIVIMED LABS LIMITED

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2024

Rs. In Million

Sl. No.	Particulars	3 Months Ended			Previous Year Ended 31.03.2024
		30.06.2024	31.03.2024	30.06.2023	
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	Income From Operations				
1	Revenue from Operations	293.73	386.16	353.51	1,490.71
	Total revenue from operations	293.73	386.16	353.51	1,490.71
2	Other Income	0.60	76.25	1.12	99.76
3	Total Revenue (1+2)	294.33	462.41	354.63	1,590.47
4	Expenses				
a	Cost of material consumed	198.17	338.86	174.65	895.45
b	Changes in inventories of finished goods work in progress and stock-in-trade	(24.62)	(200.02)	6.20	(180.71)
c	Employee Benefit Expenses	60.28	69.91	76.27	341.55
d	Finance Costs	2.97	(333.34)	106.61	24.32
e	Depreciation and Amortisation Expenses	40.09	58.35	46.99	199.41
f	Other Expenses	169.89	403.83	99.66	710.39
	Total Expenses	446.78	337.58	510.38	1,990.41
5	Profit before tax (3-4)	(152.45)	124.83	(155.75)	(399.94)
6	Prior Period Expenses		58.29		58.29
7	Tax Expenses				
	Current Taxes	-	0.18	-	0.18
	Deferred Taxes	-	13.73	-	(3.95)
	Total tax expenses	-	13.91	-	(3.77)
8	Profit for the period /Year (5-6-7)	(152.45)	52.63	(155.75)	(454.46)
9	Non-Controlling Interest				
10	Other Comprehensive income				
	Items that will not be reclassified to profit or loss, net of tax	-	5.63	-	5.63
	Items that will be reclassified to profit or loss, net of tax	-	-	-	-
	Total other comprehensive income	-	5.63	-	5.63
	Non-controlling interest				
11	Total comprehensive income (8+9)	(152.45)	58.26	(155.75)	(448.83)
12	Paid up Equity Share Capital	165.83	165.83	165.83	165.83
13	Other equity				
14	Earnings per Share (before Extraordinary Items) of Rs2 - each)				
	(a) Basic	(1.84)	0.63	(1.88)	(5.48)
	(b) Diluted	(1.78)	0.62	(1.82)	(5.32)

NOTES

- The above Consolidated financial results of Vivimed Labs Limited ("the Company") as reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on January 10, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and expressed a modified conclusion thereon.
- These Consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND-AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- In line with provisions of IND-AS 108 Operating segments, the Company has primarily in Pharma Segment and accordingly the segment reporting is not applicable to the company.
- The Company has defaulted in repayment of dues to banks and financial institution amounting to Rs 3,746.46 million as on 30.06.2024 as per books of account. All the loan accounts outstanding as on 30.06.2024 are classified as NPA by the banks. In view of ongoing negotiation with lenders for settlement, interest for the period is not accounted.
- Deferred tax will be calculated at end of year.
- Corresponding numbers of previous period year have been regrouped, wherever necessary.

Place : Hyderabad
Date : 10/01/2025




For VIVIMED LABS LIMITED
(SANTOSH VARAL VARR)
MANAGING DIRECTOR

Independent Auditor's Review Report on the Quarterly Unaudited Standalone financial results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Review report to
THE BOARD OF DIRECTORS
M/S VIVIMED LABS LIMITED

1. We have reviewed the accompanying statement of Unaudited Standalone Financial Results of **VIVIMED LABS LIMITED** ("the Company"), for the Quarter 30 June 2024 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015 as amended from time to time ("the Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing and consequently does not enable us to obtain assurance that we would be aware of all significant matters that might be identified in an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. **Basis for Qualified Conclusion**
Based on information provided to us by management, Vivimed Labs Limited has not provided for interest expenses of ₹ 83.16 million on an accrual basis, pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards
5. **Qualified Conclusion**
Based on our review, with the exception of the matter described in the preceding paragraph, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid



down in the aforesaid 'Ind AS 34' Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matters:

We have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 30th June 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 30th June 2023 are audited by the previous auditor whose report dated 14.08.2023, expressed an unmodified opinion on those Standalone financial statements.

Our Conclusion is not modified in respect of this matter.

Place: Hyderabad


Date: 10-01-2025

UDIN: 25213487BMMMJI8433

For SVRL & Co.

Chartered Accountants

Firm's Regn No: 016182S



G Ramakrishna

Partner

M. No. 213487

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Vivimed Labs Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Vivimed Labs Limited

1. We have reviewed the accompanying "Statement of Unaudited Consolidated Financial Results for the Quarter Ended 30 June 2024" (the "Statement") of Vivimed Labs Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), and its associates attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



We also performed procedures in accordance with the circular issued by SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company

1. Vivimed Labs Limited

Subsidiaries

1. Finoso Pharma Private Limited
2. Vivimed Holdings Limited
3. Vivimed Labs USA INC.
4. Vivimed Labs Mauritius Limited

Associates


1. Yantra Green Power Private Limited

5. Basis for Qualified Conclusion

Based on information provided to us by management, Holding Company has not provided for interest expenses of ₹ 83.16 million on an accrual basis, pertaining to loans [Term Loans and Working capital Loans]. This omission results in an understatement of liabilities and losses for the reporting period, thereby deviating the accrual principle as mandated by Indian accounting standards

6. Qualified Conclusion

Based on our review, with the exception of the matter described in the preceding paragraph,, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations,



including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. Other Matters:

The accompanying Statement includes unaudited interim financial results and other unaudited financial information in respect of subsidiaries, whose interim financial results and other financial information reflect total revenues of Rs. 47.94 million and total net loss after tax of Rs.1.34 million for the period 01-04-2024 to 30-06-2024 as considered in the "Statement" whose interim financial results and other financial information have not been reviewed by their auditors;

These unaudited interim financial results and other unaudited financial information have been approved and furnished to us by the Management and our conclusion on "the Statement", in so far as it relates to the affairs of subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information.

Our conclusion on "the Statement" in respect of matters stated above is not modified with respect to our reliance on the financial results certified by the Management.

Also we have not audited or reviewed the comparative financial information appearing in the statement of the corresponding quarter ended 30th June 2023. The comparative financial information appearing in the statement of the corresponding quarter ended 30th June 2023 are audited by the previous auditor whose report dated 14.08.2023, expressed an unmodified opinion on those Consolidated financial results.

Our Conclusion is not modified in respect of this matter.

Place: Hyderabad
Date: 10-01-2025

UDIN: 25213487BMMMJJ1984

For SVRL & Co.
Chartered Accountants
Firm's Regn No: 016182S

G Ramakrishna
Partner
M. No. 213487

